Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Convergence 2020 Keynote Speaker to Discuss COVID-19 & a Changing Medical Communications Industry

Catherine Kolonko  |  Issue: September 2020  |  August 6, 2020

Editor’s note: Registration for ACR Convergence 2020 is now open.

Dr. Rubin

Less than a year after becoming editor in chief of The New England Journal of Medicine (NEJM), Eric Rubin, MD, PhD, found himself in the thick of the COVID-19 pandemic. SARS-CoV-2-related submissions flooded the journal office at an unprecedented pace, making an impact on the journal’s operations and giving him a new perspective on the importance of communication.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Rubin chairs the Harvard T.H. Chan School of Public Health’s Department of Immunology and Infectious Diseases, Boston. A recognized leader in infectious diseases, he is known for his groundbreaking tuberculosis research and his dedication to often neglected patient populations.

As the keynote speaker at ACR Convergence 2020 in November (which will be presented online via an entirely virtual format), Dr. Rubin will share his perspective on, and the importance of, communication during a pandemic.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Impact of COVID-19
The Rheumatologist spoke with Dr. Rubin in late July about his experiences and what he plans to talk about in his keynote.

“At one point we were getting more than 200 COVID-19 articles, every day, seven days a week,” he says.

ZLATKO GUZMIC; VADIMZOSIMOV / SHUTTERSTOCK.COM

According to Dr. Rubin, the pandemic fueled an enormous volume of articles, stacking up more submissions in just a few months beginning in February than all of the previous year. Putting new systems in place to handle the unexpected spike in volume eventually calmed things down a bit, but the initial wave “felt overwhelming,” admits Dr. Rubin.

“We’re not a breaking news publication, but we had to get things out very quickly because a lot of what we published was only important if [it could be published in a timely manner] in the middle of the outbreak,” says Dr. Rubin.

That urgency put stress on the system, editors and staff, but it was nevertheless “a fascinating experience,” notes Dr. Rubin. Like the pandemic, the workload remained pretty much relentless as time marched on.

What to Expect
The variety of submissions Dr. Rubin and his staff received provided an abundance of material for his keynote speech, which will highlight various aspects of the COVID-19 pandemic. He expects to cover the status of vaccines under development to treat the virus and the most promising therapeutic trials, as well as the role of immunity in vaccines, convalescent plasma and interventions of inflammatory cascades.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceMeeting ReportsProfessional Topics Tagged with:ACR Convergence 2020Eric Rubin

Related Articles

    Arthritis Care & Research Celebrates 25 Years

    June 1, 2013

    From its beginnings as a quarterly journal in 1988, to a successful monthly publication today, AC&R has evolved and thrived

    COVID-19 Perspectives Shared in ACR Convergence Opening Session

    November 23, 2020

    ACR CONVERGENCE 2020—Eric Rubin, MD, PhD, took over as editor in chief of the New England Journal of Medicine in September 2019, just a few months before COVID-19 began taking over the world. Since then, Dr. Rubin’s perspective on the pandemic has been unlike that of any other person: He has led reviews of a…

    The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

    November 23, 2021

    New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

    The ACR Debuts Open Access Journal

    November 19, 2018

    The ACR will add a new professional journal, ACR Open Rheumatology, in January 2019. An open access journal, it will feature the same high-quality, rigorously peer-reviewed articles on original investigations in rheumatology research, as well as commentaries and reviews, as the ACR’s other journals, Arthritis & Rheumatology (A&R) and Arthritis Care & Research (AC&R). Co-Editors-in-Chief…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences